SuperworthLabcorp LH
- Market cap
- $26.7B
- PE
- 27.2×
- 10y median 19.4×
- Forward PE
- 17.4×
- 10y median 13.3×
- Price to sales
- 1.9×
- EV/EBIT
- 21.6×
- Revenue, 12 months
- $14.3B
- +6% on a year ago
- Net margin
- 7.0%
- Free cash flow yield
- 4.3%
Labcorp trades at 27.2× trailing earnings, pricier than 73% of the last ten years. Revenue was $14.3B over the last twelve months, up 6% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.1B+7% | $3B−17% | $3.2B+5% | $3.2B+6% | $3.3B+7% | $3.3B+10% | $3.3B+5% | $3.5B+10% | $3.6B+9% | $3.5B+6% | $3.5B+6% | $3.7B+6% | |
| Cost of revenue | $2.2B+11% | $2.2B−18% | $2.3B+4% | $2.3B+5% | $2.4B+8% | $2.4B+10% | $2.4B+5% | $2.5B+8% | $2.5B+7% | $2.5B+4% | $2.5B+5% | $2.6B+6% |
| Gross profit | $851.2M−4% | $821.4M−15% | $897.3M+6% | $926.4M+10% | $904.4M+6% | $896.3M+9% | $948M+6% | $1B+13% | $1B+13% | $993.2M+11% | $1B+7% | $1.1B+6% |
| SG&A | $525.5M+16% | $532.9M−1% | $508.4M+11% | $557.8M+10% | $568.6M+8% | $595.2M+12% | $546M+7% | $579.3M+4% | $552.4M−3% | $538.6M−10% | $551M+1% | $577.2M−0% |
| $252.3M−33% | −$122.8M | $321.3M−3% | $294.8M+11% | $254.1M+1% | $216.5M | $326M+2% | $394.5M+34% | $396.6M+56% | $267.6M+24% | $380.8M+17% | $451.6M+15% | |
| Interest expense | $50.3M+9% | $48.8M−1% | $46.9M−8% | $47.6M−4% | $50.4M+0% | $63.4M+30% | $56M+19% | $57.1M+20% | $56M+11% | $55M−13% | $55.1M−2% | $61.1M+7% |
| Pre-tax income | $238.7M−24% | −$147.1M | $297.4M+9% | $267.7M+31% | $210.6M−12% | $183.8M | $275.2M−8% | $304.7M+14% | $337M+60% | $190.6M+4% | $319.7M+16% | $386.4M+27% |
| $55.1M+44% | $19.7M | $69.1M+8% | $62.1M+25% | $41M−26% | $40.2M+104% | $62.2M−10% | $66.4M+7% | $75.5M+84% | $25.7M−36% | $41.7M−33% | $87.3M+32% | |
| Net income | $183.3M−48% | −$167.1M | $228M+7% | $205.3M+9% | $169.3M−8% | $143.4M | $212.8M−7% | $237.9M+16% | $261.1M+54% | $164.7M+15% | $277.8M+31% | $298.7M+26% |
| $2.11−46% | −$1.97 | $2.69+13% | $2.43+15% | $2.00−5% | $1.71 | $2.52−6% | $2.84+17% | $3.12+56% | $1.98+16% | $3.35+33% | $3.64+28% | |
| 87M−4% | 84.7M−5% | 84.7M−5% | 84.3M−5% | 84.4M−3% | 84.1M−1% | 84.3M−1% | 83.9M−1% | 83.7M−1% | 83.2M−1% | 82.9M−2% | 82M−2% |
EPS, diluted: Q4 FY08 and Q4 FY09: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 14 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q2 FY08 to Q1 FY09: not printed by the filing, worked out from its own lines. 16 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q2 FY13: share-days: the 6-month average less the 3-month, weighted by days. Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $3.8B | $3.7B to $3.8B | $4.64 | $4.62 to $4.66 | 10 |
| Q4 FY26 | $3.7B | $3.7B to $3.7B | $4.47 | $4.44 to $4.53 | 10 |
| Q1 FY27 | $3.7B | $3.7B to $3.7B | $4.59 | $4.55 to $4.62 | 8 |
| Q2 FY27 | $3.9B | $3.9B to $3.9B | $5.23 | $5.18 to $5.26 | 8 |
| Q3 FY27 | $3.9B | $3.9B to $4B | $5.05 | $5.00 to $5.08 | 8 |
| Q4 FY27 | $3.9B | $3.9B to $3.9B | $4.90 | $4.86 to $4.93 | 8 |
| Q1 FY28 | $3.9B | $3.8B to $3.9B | $4.92 | $4.88 to $4.95 | 9 |
| Q2 FY28 | $4B | $4B to $4.1B | $5.46 | $5.41 to $5.50 | 9 |
Peers
Companies in Medical - Diagnostics & Research nearest Labcorp's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| Peer median | $37.1B | 39.3× | 34.7× | 31.5× | 6.7× | +8% | 13.4% |
More on Labcorp
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 17Diagnostics and research stocks with the fastest earnings growth
- #3of 20Diagnostics and research stocks with the lowest PE ratio
- #5of 25Diagnostics and research stocks with the lowest EV/EBIT
- #7of 28Diagnostics and research stocks with the highest free cash flow yield
- #9of 15Diagnostics and research stocks cheapest against their own PE history
- #9of 11Diagnostics and research stocks with the fastest expected revenue growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .